Asthma

Atrial Fibrillation

Autoimmune Diseases

Biosimilars

Blood Cancer

COVID-19

Cardiovascular Diseases

Dermatology

Diabetes

Digital Health

Eyecare

Gene Therapy

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pediatrics

Plaque Psoriasis

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Reproductive Health

Respiratory Conditions

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Supplements And Featured Publications

Events

2023 PBMI Annual National Conference

Virtual Events

CME/CE

Resources

PBM Leaders

Subscribe

Print Subscription

eNewsletter

Articles

As of today, 40 states and Washington, D.C., have expanded their Medicaid programs under the Affordable Care Act. 

North Carolina Officially Launches Medicare Expansion

Cigna has been looking to sell its Medicare Advantage business, perhaps as a way to fend off antitrust objection to the deal.

  Cigna, Humana in Talks To Combine, Reports WSJ

CTTP is rare hereditary blood clotting disorder stemming from a disease-causing mutation in the ADAMTS13 gene. This gene plays a crucial role in producing the ADAMTS13 enzyme, responsible for regulating blood clotting. 


FDA Approves Adzynma for Rare Blood Clotting Disorder cTTP

FDA has approved a new therapy for HR positive breast cancer and announces plan to hold advisory meeting for Abecma in earlier treatment of multiple myeloma. In addition, Janssen has submitted a supplemental application for Rybrevant in NSCLC.

FDA Updates for the Week of Nov. 20, 2023

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

Twitter

LinkedIn

Resource Centers

Covid-19

Eye Care

Spotlight

AMCP Annual

ASRS

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

As the nation debates the future of our healthcare system, one idea gaining attention is a “Medicare-for-all” single-payer national health insurance plan.

Opinion: Medicare for all: Imminent or pipe dream?

Mark Scott

Articles